Association of hypercoagulability with disease progression under

Association of hypercoagulability with disease progression under immunotherapy. A case control study Two groups of patients were compared in a study. Baseline characteristics were well balanced selleck chem Cisplatin and these groups were compared by modified MSKCC prognostic score includ ing predictors of short survival from ARCC trial. Sixteen patients of study group and eight patients of Inhibitors,Modulators,Libraries control group had disease progression after 2 treatment cycles. Differences between two groups were significant. Disease control rate Partial response Stable disease was significant higher in patients with normal coagulation 1 CR 5 PR 14 versus 0 CR 1 PR 11 SD. In Kaplan Meier analysis, Inhibitors,Modulators,Libraries patients with hypercoagulabil ity had a significantly shorter overall survival than patients with normal coagulation. Median survival was 8.

2 and 14. 6 months, respectively. Survival curves are given in Figure 1. Multivariate analysis In univariate analysis, patients with hypercoag ulability had significantly shorter survival than Inhibitors,Modulators,Libraries patients with normal coagulation. median survivals of 8. 9 and 16. 3, respectively. Additional factors that were also associated with poor sur vival were MSKCC prognostic factors, increasing ECOG performance status, shot time from diagnosis, non clear cell histology, and the presence of liver or bone metasta sis, more than 1 metastatic site. Because of the large number of factors that were associ ated with hypercoagulability and or survival in general study population, multivariable analyses were conducted to determine whether hypercoagulability was an inde pendent predictor.

The results of this analysis Inhibitors,Modulators,Libraries are summa rized in Table 4. By using stepwise variable selection, hypercoagulability, MSKCC risk group, non clear RCC, number of metastatic sites, and age were found to be independent predictors of survival. Discussion Although advances in the treatment of metastatic RCC have been made in recent years, the overall outcome of this disease remains dismal. Despite encouraging results with new treatment agents, their optimal incorporation into clinical practice remains to be defined. Whether these agents should be used as monotherapy or combined with cytokines or other agents remains speculative. The role of prognostic factors may help to define better these ques tions. We sought to analyze metastatic RCC patients before can cer specific treatment in N. N.

Blokhin Russian Inhibitors,Modulators,Libraries Cancer Research Center. The objective of this study was to PD 0332991 deter mine whether an elevated coagulation level is a negative predictor for survival and response to treatment in meta static RCC. Coagulation estimate is a simple, inexpensive test that can be obtained before treatment and could help to individualize therapy based on risk factor assessment. Our results showed that 40% of patients had hypercoagu lability at treatment start. Hypercoagulability can be an independent prognostic factor according to our data.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>